Pleural	JJ
mesothelial	JJ
cells	NNS
in	IN
pleural	JJ
and	CC
lung	NN
diseases	NNS
.	.

During	IN
development	NN
,	,
the	DT
mesoderm	NN
maintains	VBZ
a	DT
complex	JJ
relationship	NN
with	IN
the	DT
developing	VBG
endoderm	NN
giving	VBG
rise	NN
to	TO
the	DT
mature	JJ
lung	NN
.	.

Pleural	JJ
mesothelial	JJ
cells	NNS
(	(
PMCs	NNS
)	)
derived	VBN
from	IN
the	DT
mesoderm	NN
play	VB
a	DT
key	JJ
role	NN
during	IN
the	DT
development	NN
of	IN
the	DT
lung	NN
.	.

The	DT
pleural	JJ
mesothelium	NN
differentiates	VBZ
to	TO
give	VB
rise	NN
to	TO
the	DT
endothelium	NN
and	CC
smooth	VB
muscle	NN
cells	NNS
via	IN
epithelial-to-mesenchymal	JJ
transition	NN
(	(
EMT	NN
)	)
.	.

An	DT
aberrant	JJ
recapitulation	NN
of	IN
such	JJ
developmental	JJ
pathways	NNS
can	MD
play	VB
an	DT
important	JJ
role	NN
in	IN
the	DT
pathogenesis	NN
of	IN
disease	NN
processes	NNS
such	JJ
as	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
.	.

The	DT
PMC	NN
is	VBZ
the	DT
central	JJ
component	NN
of	IN
the	DT
immune	JJ
responses	NNS
of	IN
the	DT
pleura	NN
.	.

When	WRB
exposed	VBN
to	TO
noxious	JJ
stimuli	NNS
,	,
it	PRP
demonstrates	VBZ
innate	JJ
immune	JJ
responses	NNS
such	JJ
as	IN
Toll-like	JJ
receptor	NN
(	(
TLR	NN
)	)
recognition	NN
of	IN
pathogen	NN
associated	VBN
molecular	JJ
patterns	NNS
as	RB
well	RB
as	IN
causes	VBZ
the	DT
release	NN
of	IN
several	JJ
cytokines	NNS
to	TO
activate	VB
adaptive	JJ
immune	JJ
responses	NNS
.	.

Development	NN
of	IN
pleural	JJ
effusions	NNS
occurs	VBZ
due	JJ
to	TO
an	DT
imbalance	NN
in	IN
the	DT
dynamic	JJ
interaction	NN
between	IN
junctional	JJ
proteins	NNS
,	,
n-cadherin	NN
and	CC
b-catenin	NN
,	,
and	CC
phosphorylation	NN
of	IN
adherens	NNS
junctions	NNS
between	IN
PMCs	NNS
,	,
which	WDT
is	VBZ
caused	VBN
in	IN
part	NN
by	IN
vascular-endothelial-growth-factor	NN
(	(
VEGF	NN
)	)
released	VBN
by	IN
PMCs	NNS
.	.

PMCs	NNS
play	VBP
an	DT
important	JJ
role	NN
in	IN
defense	NN
mechanisms	NNS
against	IN
bacterial	JJ
and	CC
mycobacterial	JJ
pleural	JJ
infections	NNS
,	,
and	CC
in	IN
pathogenesis	NN
of	IN
malignant	JJ
pleural	JJ
effusion	NN
,	,
asbestos	NN
related	JJ
pleural	JJ
disease	NN
and	CC
malignant	JJ
pleural	JJ
mesothelioma	NN
.	.

PMCs	NNS
also	RB
play	VBP
a	DT
key	JJ
role	NN
in	IN
the	DT
resolution	NN
of	IN
inflammation	NN
,	,
which	WDT
can	MD
occur	VB
with	IN
or	CC
without	IN
fibrosis	NN
.	.

Fibrosis	NN
occurs	VBZ
as	IN
a	DT
result	NN
of	IN
disordered	VBN
fibrin	JJ
turnover	NN
and	CC
due	JJ
to	TO
the	DT
effects	NNS
of	IN
cytokines	NNS
such	JJ
as	IN
transforming-growth-factor-b	NN
,	,
platelet-derived	JJ
growth	NN
factor	NN
(	(
PDGF	NN
)	)
,	,
and	CC
basic	JJ
fibroblast	NN
growth	NN
factor	NN
;	:
which	WDT
are	VBP
released	VBN
by	IN
PMCs	NNS
.	.

Recent	JJ
studies	NNS
have	VBP
demonstrated	VBN
a	DT
role	NN
for	IN
PMCs	NNS
in	IN
the	DT
pathogenesis	NN
of	IN
IPF	NN
suggesting	VBG
their	PRP$
potential	JJ
as	IN
a	DT
cellular	JJ
biomarker	NN
of	IN
disease	NN
activity	NN
and	CC
as	IN
a	DT
possible	JJ
therapeutic	JJ
target	NN
.	.

Pleural-based	JJ
therapies	NNS
targeting	VBG
PMCs	NNS
for	IN
treatment	NN
of	IN
IPF	NN
and	CC
other	JJ
lung	NN
diseases	NNS
need	VBP
further	JJ
exploration	NN
.	.

